Across TCGA pan-cancer cohorts, POLR2J3 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated POLR2J3 data layer compared with 24 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher POLR2J3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated POLR2J3 expression acts as an unfavorable survival marker.
SKCM are the cancer types where POLR2J3 Mutation most reproducibly stratifies survival.